Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial
Sarbani Ghosh Laskar(Tata Memorial Hospital), Jaiprakash Agarwal(Tata Memorial Hospital), Nikhil Kalyani(Tata Memorial Hospital), Vedang Murthy(Homi Bhabha National Institute), Pankaj Chaturvedi(Tata Memorial Hospital), Manju Sengar(Homi Bhabha National Institute), Devendra Chaukar(Tata Memorial Hospital), Ashwini Budrukkar(Tata Memorial Hospital), Prathamesh Pai(Tata Memorial Hospital), Anil D′Cruz(Apollo Hospitals), Tejpal Gupta(Tata Memorial Hospital)
Cited by 69
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
|European Urology|2020|396
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
|European Journal of Nuclear Medicine and Molecular Imaging|2011|377
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
|Journal of Clinical Oncology|2017|340